Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

For Consumers

New 300 mg Reyataz capsule approved

On October 16, 2006, the Food and Drug Administration approved a new 300 mg capsule form of Reyataz (atazanavir).

Reyataz is now available as 100mg, 150 mg, 200 mg, and the new 300 mg capsules.

The new 300 mg capsules give treatment-experienced patients the option to take either one 300 mg capsule, or two 150 mg capsules of Reyataz, once daily plus ritonavir 100 mg once daily, with food.

The recommended dose for treatment-naïve patients remains unchanged and is Reyataz 400 mg (two 200mg capsules) once daily with food.

Reyataz is a product of Bristol-Myers Squibb.

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

Page Last Updated: 08/06/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.